Document Detail


Effects of growth hormone withdrawal in obese premenopausal women.
MedLine Citation:
PMID:  23146135     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: We previously reported improved body composition and cardiovascular risk markers plus a small decrease in glucose tolerance with GH administration vs placebo for 6 months to abdominally obese premenopausal women. The objective of this study was to determine whether the effects of GH treatment on cardiovascular risk markers, body composition and glucose tolerance in obese women persist 6 months after GH withdrawal.
DESIGN AND PATIENTS: Fifty abdominally obese premenopausal women completed a trial of rhGH vs placebo for 6 months; thirty-nine women completed a subsequent 6-month withdrawal observation period.
MEASUREMENTS: IGF-I, body composition by CT, (1) H-MRS and DXA, serum cardiovascular risk markers, oral glucose tolerance test (OGTT).
RESULTS: IGF-I standard deviation scores (SDS) within the GH group were -1.7 ± 0.1 (pretreatment),-0.1 ± 0.3 (after 6 months of GH) and -1.7 ± 0.1 (6 months post-GH withdrawal). Six months after GH withdrawal, total abdominal and subcutaneous adipose tissue, total fat, trunk fat, trunk/extremity fat, hsCRP, apoB, LDL, and tPA were higher than at the 6-month (GH discontinuation) timepoint (P ≤ 0.05). All body composition and cardiovascular risk markers that had improved with GH returned to baseline levels by 6 months after GH discontinuation, as did fasting and 2-h OGTT glucose levels.
CONCLUSION: The effects of GH administration to abdominally obese premenopausal women have a short time-course. The beneficial effects on body composition and cardiovascular risk markers, and the side effect of altered glucose tolerance returned to pretreatment levels after GH withdrawal. There was no suppression of endogenous IGF-I levels, which returned to baseline after GH withdrawal.
Authors:
E Lin; M A Bredella; A V Gerweck; M Landa; D Schoenfeld; A L Utz; K K Miller
Related Documents :
21823855 - A series of advantage suburethral slings.
22042725 - Completion and return of fall diaries varies with participants' level of education, fir...
10962355 - Long-term trends in the incidence of paget's disease of bone.
15383405 - Risk of connective tissue disorders among breast implant patients.
3303305 - Longitudinal study of group b streptococcal carriage during late pregnancy.
20126835 - Venous thromboembolism during pregnancy, postpartum or during contraceptive use.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Clinical endocrinology     Volume:  78     ISSN:  1365-2265     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-04-23     Completed Date:  2013-10-28     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  914-9     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons Ltd.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00131378
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Blood Glucose / metabolism
Body Composition / drug effects
Cardiovascular Diseases / chemically induced
Female
Glucose Tolerance Test
Human Growth Hormone / administration & dosage,  adverse effects*
Humans
Insulin-Like Growth Factor I / metabolism
Middle Aged
Obesity / drug therapy*
Premenopause
Risk Factors
Substance Withdrawal Syndrome / physiopathology*
Grant Support
ID/Acronym/Agency:
K23 RR-23090/RR/NCRR NIH HHS; K24 HL092902/HL/NHLBI NIH HHS; M01 RR001066/RR/NCRR NIH HHS; R01 HL-077674/HL/NHLBI NIH HHS; R01 HL077674/HL/NHLBI NIH HHS; T32 DK007028/DK/NIDDK NIH HHS; UL1 RR-025758/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Blood Glucose; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Novel wine yeast with mutations in YAP1 that produce less acetic acid during fermentation.
Next Document:  Immunological Basis of Melanoma-Associated Vitiligo-Like Depigmentation.